The transaction includes $70m in cash and a $20m retained equity position for Nektar in a new Ampersand portfolio company.

After a protracted rough patch—which has included layoffs, partnership terminations and lawsuits—San Francisco’s Nektar ...

The latest update is out from Nektar Therapeutics ( (NKTR) ).

Therapeutics announced that it has entered into a definitive agreement to sell its Huntsville, Alabama manufacturing facility and ...

Fintel reports that on November 4, 2024, Piper Sandler initiated coverage of Nektar Therapeutics (NasdaqCM:NKTR) with a ...

Nektar Therapeutics (Nasdaq: NKTR), a global biotechnology company focused on the discovery and development of novel therapies to treat autoimmune disorders, today announced that it has entered into a ...

California, USA-based biotech Nektar Therapeutics’ (Nasdaq: NKTR) shares closed up more than 8% at $1.33 yesterday after it ...

Piper Sandler has initiated coverage on Nektar Therapeutics Inc (NASDAQ:NKTR), citing the company’s lead asset ...

On Monday, Nektar Therapeutics (NKTR) stock saw a modest uptick, ending the day at $1.33 which represents a slight increase of $0.10 or 8.13% from the prior close of $1.23. The stock opened at $1.37 ...

Short interest in Nektar Therapeutics (NASDAQ:NKTR) decreased during the last reporting period, falling from 7.76M to 7.31M. This put 5.08% of the company's publicly available shares short.

Nektar shed 70% of its workforce as a result and refocused its R&D on NKTR-358, an IL-2 conjugate regulatory T cell stimulator for inflammatory conditions like lupus and atopic dermatitis ...

The biggest firm on the list is Nektar Therapeutics, which is developing the promising immunotherapy NKTR-214. The report values San Francisco-based Nektar at $17 billion thanks to its multi ...